Ailanthone targets mitophagy-loaded SIRT4 to facilitate the deacetylation of HIF1α, triggering oxidative stress for gastric carcinoma treatment

Our results revealed that AIL targeted mitophagy-loaded SIRT4 to regulate redox homeostasis, inducing mitochondrial dysfunction-mediated cell apoptosis and inhibiting gastric cancer growth. These findings provide strong evidence for the potential clinical use of AIL in gastric cancer treatment.